RVMD vs. ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, and QGEN
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Revolution Medicines has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.
Revolution Medicines has a net margin of 0.00% compared to BeOne Medicines' net margin of -9.40%. BeOne Medicines' return on equity of -7.55% beat Revolution Medicines' return on equity.
In the previous week, Revolution Medicines had 8 more articles in the media than BeOne Medicines. MarketBeat recorded 11 mentions for Revolution Medicines and 3 mentions for BeOne Medicines. Revolution Medicines' average media sentiment score of 0.96 beat BeOne Medicines' score of 0.61 indicating that Revolution Medicines is being referred to more favorably in the media.
Revolution Medicines presently has a consensus price target of $67.58, indicating a potential upside of 82.66%. BeOne Medicines has a consensus price target of $320.67, indicating a potential upside of 30.62%. Given Revolution Medicines' higher possible upside, analysts clearly believe Revolution Medicines is more favorable than BeOne Medicines.
Revolution Medicines has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
Revolution Medicines beats BeOne Medicines on 11 of the 15 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 7/5/2025 by MarketBeat.com Staff
